The present invention relates to pyrrazolo-pyrimidine derivatives of formula (I):
wherein R
1
to R
4
and A are as defined in the specification, a process for the manufacture thereof, their use for treating or preventing metabotropic glutamate receptors mediated disorders, their use for the preparation of medicaments for treating such disorders and pharmaceutical compositions containing said derivatives.
Heteroaryl-Ureas and Their Use as Glucokinase Activators
申请人:Murray Anthony
公开号:US20090216013A1
公开(公告)日:2009-08-27
This invention relates to compounds of formula (I)
which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
Heteroaryl-ureas and their use as glucokinase activators
申请人:Murray Anthony
公开号:US20070054897A1
公开(公告)日:2007-03-08
This invention relates to compounds of formula (I)
which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS
申请人:Murray Anthony
公开号:US20110060019A1
公开(公告)日:2011-03-10
This invention relates to compounds of formula (I)
which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
The present invention describes 2,3-di-substituted N-heteroaromatic propionamides, of Formula (I) wherein the substitution at the 3-position is an optionally substituted phenyl ring and the substitution at the 2-position is an alkyl or cycloalkyl group; pharmaceutical compositions comprising the same; and, methods of using the same. The propionamides are glucokinase activators for the treatment of type II diabetes.